medigraphic.com
ISSN 1684-1824 (Electronic)

2015, Number 3

<< Back Next >>

Rev Méd Electrón 2015; 37 (3)

A propos of a case of gangliosidosis GM. Type II. Sandhoff disease

González LI, Sierra BEM, León PMQ, Leiva GML, Hernández DS, González FY

Language: Spanish
References: 12
Page: 263-271
PDF size: 264.28 Kb.


ABSTRACT

Gangliosidosis are a group of hereditary diseases of lysosomal storage, due to an accumulation of gangliosides, especially in the neurons. The cause is the dysfunction of several lysosomal enzymes in the way of the gangliosides degradation. There are several forms of gangliosidesis, like GM1 and GM2. We present the case of a 33-years-old patient who was previously diagnosed with lateral amyotrophic sclerosis. Because of several symptoms he presented we carried out some complementary exams showing as a result a gangliosidosis GM-2 Type II or Sandhoff disease.


REFERENCES

  1. Suzuki Y, Sakuraba H, Oshima A. Galactosidase deficiency (Galactosidosis): GM 1 Gangliosidosis and Morquio B Disease. En: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Online Metabolic and Molecular Bases of Inherited Disease [Internet]. New York: McGraw-Hill; 2012 [citado 16 Dic 2014]. Disponible en: http://www.ommbid.com/OMMBID/the_online_metabolic_and_molecular_bases_of _inherited_disease /b/abstract/part16/ch151

  2. Pozo Alonso AJ, Pozo Lauzán DR, Estol de la Guardia N, Menéndez Sainz C. Enfermedad de Tay-Sachs. Rev Cubana Pediatr [Internet]. 2014 [citado 17 Dic 2014];86(4):529-34. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75312014000400014&nrm=iso

  3. Menéndez Sainz MC. Diagnóstico enzimático de las enfermedades de almacenamiento lisosomal: experiencia de 20 años [tesis para optar por el grado de Doctor en Ciencias de la Salud]. La Habana: Universidad de Ciencias Médicas de La Habana; 2012 [citado 17 Dic 2014]. Disponible en: http://tesis.repo.sld.cu/423/1/MenendezSainzL.pdf

  4. Uribe A. Hexosaminidasas y enfermedades neurodegenerativas. Iatreia [Internet]. 2011 [citado 18 Dic 2014];23(4). Disponible en: http://aprendeenlinea.udea.edu.co/revistas/index.php/iatreia/article/viewArticle/81 95

  5. Neufeld EF, Muenzer J. The Mucopolysaccharidoses. En: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Online Metabolic and Molecular Bases of Inherited Disease [Internet]. New York: McGraw-Hill; 2013 [citado 16 Dic 2014]. Disponible en: http://www.ommbid.com/OMMBID/the_online_metabolic_and_molecular_bases_of _inherited_disease/b /abstract/part16/ch136

  6. Caciotti A, Garman S, Rivera Y, Procopio E, Catarzi S, Ferri L, et al. GM 2 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim Biophys [Internet]. 2011 [citado 17 Dic 2014];1812(7). Citado en PubMed; PMID: 21497194.

  7. d'Azzo A, Andria G, Strisciuglio P, Galjaard H. Galactosialidosis. En: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Online Metabolic and Molecular Bases of Inherited Disease [Internet]. New York: McGraw-Hill; 2010 [citado 18 Dic 2014]. Disponible en: http://www.ommbid.com/OMMBID/the_online_metabolic_and_molecular_bases_of _inherited_disease/b /abstract/part16/ch152

  8. Hernández García I, Seiglie Díaz F, Campos Hernández D, Marrón Portarles L, Díaz González JL, Carmona Padrón O. Gangliosidosis generalizada tipo 1. Rev Cubana Pediatr [Internet]. 2014 [citado 16 Nov 2014];86(1):103-7. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75312014000100013&nrm=iso

  9. Jeyakumar M, Thomas R, Smith E, Smith D, van der Spoel A, Hugh Perry V, et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain [Internet]. 2003 [citado 18 Dic 2014];126(4):974-87. Disponible en: http://brain.oxfordjournals.org/content/126/4/974

  10. Mahuran DJ. Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease [Internet]. 1999 [citado 18 Dic 2014];1455(2-3):105-38. Disponible en: http://www.sciencedirect.com/science/article/pii/S0925443999000745

  11. Clarkea JT, Mahurana DJ, Satheb S, Kolodnyb EH, Rigata BA, Raimana JA, et al. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay–Sachs or Sandhoff variants). Molecular Genetics and Metabolism [Internet]. 2011 [citado 18 Dic 2014];102(1):6-

  12. Disponible en: http://www.sciencedirect.com/science/article/pii/S1096719210003458




2020     |     www.medigraphic.com